Point taken. But isn't it true that every diagnostic product in the market faces continuous competition from competitors trying to advance new products into that market? Even with that continual competition, there are plenty of examples of diagnostic tests that have captured the majority of market share in their specialized area. First to market and gaining support of KOLs is key to establishing a strong foothold. LymPro is first to market for blood-based AD tests. Gerald now has the option of bringing two of the leading alternative detection methodologies to market alongside LymPro.
Perhaps I should have used a different term than "corner" the market, although I do remember him using those words in a recent presentation. I don't believe it's wishful thinking at all, since the company is likely to garner the majority of the blood-based diagnosing testing business for AD. Who else is close to having blood-based tests commercialized?
I'll simply refer back to the press release announcing the licensing option.
Perhaps I should have used a different term than "corner" the market, although I do remember him using those words in a recent presentation. I don't believe it's wishful thinking at all, since the company is likely to garner the majority of the blood-based diagnosing testing business for AD. Who else is close to having blood-based tests commercialized?
I'll simply refer back to the press release announcing the licensing option.
http://ir.amarantus.com/company-news/detail/1...rs-diseaseQuote:" The evaluation of the memory loss-related biomarkers from Georgetown University and University of Rochester are part of our continuing plan to be the world's premier Alzheimer's blood-based diagnostic company in the world ," said Gerald E. Commissiong, President & CEO of Amarantus. "There are six patents covered in the agreement with Georgetown University. The technologies are based on metabolic, genetic and exosomal biomarkers. We believe these may hold additional potential for identifying distinguishing factors in dementia and Alzheimer's disease that will be complementary to our current cell cycle dysregulation platform with LymPro(R) Test. With the potential addition of these biomarkers to our Alzheimer's diagnostics portfolio, we are positioning ourselves to be able to serve the pharmaceutical clinical trial community with all three modalities (cell cycle dysregulation, lipidomics and exosomes) that will streamline their efforts to recruit and monitor subjects enrolling in Alzheimer's therapeutics clinical studies, in addition to bringing to market blood diagnostics for Alzheimer's disease that will help individuals and nations implement robust screening initiatives to accurately diagnose Alzheimer's disease."
